Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell cortex

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Cell cortex. Displaying page 1 of 1.
    EudraCT Number: 2021-002528-18 Sponsor Protocol Number: RESCUE2131PE9 Start Date*: 2022-02-22
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency; A multicentre, randomised, double blinded, placebo-controlled clinical trial on health-re...
    Medical condition: Glucocorticoid-induced adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001369 Adrenal insufficiency NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003062-18 Sponsor Protocol Number: 4071 Start Date*: 2008-06-05
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: Immunotherapeutic Rescue of steroidogenic function in autoimmune Addison’s Disease (RAD): Pilot study
    Medical condition: Autoimmune Addison's disease (adrenocortical failure)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001343 Adrenal cortical hypofunctions HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-006121-65 Sponsor Protocol Number: 65411807 Start Date*: 2021-08-31
    Sponsor Name:Odense University Hospital
    Full Title: STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ...
    Medical condition: To investigate the effects of hydrocortisone replacement in participants with previous PMR and GCA, who are in GC-free remission and exhibit biochemical evidence of mild to moderate adrenal insuffi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001369 Adrenal insufficiency NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004076-34 Sponsor Protocol Number: 7487-CL-0209 Start Date*: 2014-02-27
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003396-19 Sponsor Protocol Number: EOADR1-19 Start Date*: 2020-05-28
    Sponsor Name:Enterome
    Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adr...
    Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC) - malignant pheochromocytoma/paraganglioma (MPP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075444 Malignant paraganglioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001973-21 Sponsor Protocol Number: GNC-402 Start Date*: 2021-07-09
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004822-15 Sponsor Protocol Number: GNC-401 Start Date*: 2020-05-18
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001802-27 Sponsor Protocol Number: F002MH0218_1 Start Date*: 2019-04-16
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.
    Medical condition: Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    20.0 10014698 - Endocrine disorders 10001341 Adrenal cortical hyperfunctions HLT
    20.0 10014698 - Endocrine disorders 10001376 Adrenal neoplasms HLT
    20.0 100000004864 10001378 Adrenal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004023-24 Sponsor Protocol Number: PRETEC-EPO Start Date*: 2016-12-15
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet
    Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO)
    Medical condition: Bipolar disorder and unipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000991-41 Sponsor Protocol Number: EMN19 Start Date*: 2019-07-24
    Sponsor Name:Stichting European Myeloma Network
    Full Title: Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease
    Medical condition: Multiple Myeloma patients presenting with extramedullary disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001572-42 Sponsor Protocol Number: FCN-159-002 Start Date*: 2021-12-21
    Sponsor Name:Shanghai Fosun Pharmaceutical Industrial Development Co.,Ltd.
    Full Title: A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult...
    Medical condition: Participants diagnosed with Neurofibromatosis NF1-related plexiform neurofibromas (PN) and symptomatic with requirement of systematic therapy per investigator’s judgment. A PN is defined as a neuro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:14:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA